114114-88-4Relevant articles and documents
Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor
Wang, Beilei,Wu, Jiaxin,Wu, Yun,Chen, Cheng,Zou, Fengming,Wang, Aoli,Wu, Hong,Hu, Zhenquan,Jiang, Zongru,Liu, Qingwang,Wang, Wei,Zhang, Yicong,Liu, Feiyang,Zhao, Ming,Hu, Jie,Huang, Tao,Ge, Juan,Wang, Li,Ren, Tao,Wang, Yuxin,Liu, Jing,Liu, Qingsong
, p. 896 - 916 (2018)
Through a structure-guided rational drug design approach, we have discovered a highly selective inhibitor compound 40 (JSH-150), which exhibited an IC50 of 1 nM against CDK9 kinase in the biochemical assay and achieved around 300–10000-fold selectivity over other CDK kinase family members. In addition, it also displayed high selectivity over other 468 kinases/mutants (KINOMEscan S score(1) = 0.01). Compound 40 displayed potent antiproliferative effects against melanoma, neuroblastoma, hepatoma, colon cancer, lung cancer as well as leukemia cell lines. It could dose-dependently inhibit the phosphorylation of RNA Pol II, suppress the expression of MCL-1 and c-Myc, arrest the cell cycle and induce the apoptosis in the leukemia cells. In the MV4-11 cell-inoculated xenograft mouse model, 10 mg/kg dosage of 40 could almost completely suppress the tumor progression. The high selectivity and good in vivo PK/PD profile suggested that 40 would be a good pharmacological tool to study CDK9-mediated physiology and pathology as well as a potential drug candidate for leukemia and other cancers.
Stereocontrolled C(sp3)-P bond formation with non-activated alkyl halides and tosylates
Yang, Chu-Ting,Han, Jun,Liu, Jun,Li, Yi,Zhang, Fan,Gu, Mei,Hu, Sheng,Wang, Xiaolin
, p. 24652 - 24656 (2017/07/11)
The C(sp3)-P bond is formed via the reaction between P-H compounds and non-activated alkyl electrophiles, especially secondary alkyl halides and tosylates. This reaction proceeds via an SN2 mechanism with inversion of configuration, so it can be used to form C-P bonds with stereocontrol from chiral secondary alcohols.
PHENYL-HETEROARYL AMINE COMPOUNDS AND THEIR USES
-
Page/Page column 91, (2012/06/01)
The present invention provides a compound of formula (I): and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds of Formula I, and pharmaceutical compositions comprising such compounds